Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study.
Fiche publication
Date publication
mars 2022
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe
Tous les auteurs :
Guillaume Z, Colomba E, Thouvenin J, Saldana C, Campedel L, Dumont C, Laguerre B, Maillet D, Vicier C, Rolland F, Borchiellini D, Barthelemy P, Albiges L, Auclin E, Roulleaux Dugage M, Oudard S, Thibault C
Lien Pubmed
Résumé
Collecting duct carcinoma (CDC) and renal medullary carcinoma (RMC) are two rare subtypes of kidney cancer with a poor prognosis in the metastatic setting. Beyond first-line treatment, there are no standard-of-care therapies. This retrospective study assessed the efficacy of treatments after first-line chemotherapy in 57 patients with metastatic (m) CDC ( = 35) or RMC ( = 22) treated between 2010 and 2019 at 11 French centers. The median age was 53 years; overall, 60% ( = 34) of patients were metastatic at diagnosis. After a median follow-up of 13 months, the median overall survival was 12 (95% CI, 11-16) months. All patients received first-line platinum chemotherapy ± bevacizumab, with a median time to progression of 7.27 (95% CI, 7-100 months and an objective response rate (ORR) of 39% (95% CI, 26-52%). Patients received a median of two (1-5) treatment lines. Subsequent treatments included tyrosine kinase inhibitors ( = 12), chemotherapy ( = 34), and checkpoint inhibitors ( = 20), with ORR ranging 10-15% and disease control rates ranging 24-50%. The duration of response for all treatments was ~2 months. Notably, nine patients with CDC were still alive > two years after metastatic diagnosis. Beyond first-line therapy, treatments showed very low antitumor activity in mCDC/RMC. A better understanding of the biology of those rare tumors is urgently needed in order to identify potential targets.
Mots clés
Bellini carcinoma, collecting duct carcinoma, immune checkpoint inhibitors, metastatic renal medullary, tyrosine kinase inhibitors
Référence
Cancers (Basel). 2022 Mar 25;14(7):